Shlomo Melmed
Cedars-Sinai Medical Center · Cedars-Sinai Medical Center, Pituitary Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
8
all conditions, ClinicalTrials.gov
NIH grants tied to them
20
2 more share only the name and are not shown
Trial papers
18
PubMed author-name match
Trials
Studies that name Shlomo Melmed as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:29 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03774446 · Multicenter Study of Seliciclib (R-roscovitine) for Cushing DiseaseCedars-Sinai Medical Center · completed · Cushing Disease · principal investigator
- Ph2NCT02160730 · Treatment of Cushing's Disease With R-roscovitineShlomo Melmed, MD · terminated · Cushings Disease · principal investigator
- N/ANCT01538966 · Acromegaly Combination Treatment StudyCedars-Sinai Medical Center · terminated · Acromegaly · principal investigator
- Ph3NCT01412424 · Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for AcromegalyChiasma, Inc. · completed · Acromegaly · study chair
- N/ANCT01261000 · Tissue Biomarker for Pegvisomant ActionCedars-Sinai Medical Center · completed · Acromegaly · principal investigator
- N/ANCT00973557 · The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary FunctionCedars-Sinai Medical Center · completed · Colorectal Cancer, Lung Cancer, Breast Cancer · principal investigator
- N/ANCT00815204 · Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress DisorderCedars-Sinai Medical Center · completed · Posttraumatic Stress Disorder · study director
- N/ANCT00599092 · Pituitary Tumor Surveillance: Pathogenic CorrelationCedars-Sinai Medical Center · recruiting · Pituitary Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Mechanisms for GH action on epithelial cellsR01DK113998 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 2018 to 2026 · $367,400 awarded in 2026Same name and institution; not confirmed by an ID
- Ph 2 Multicenter study of seliciclib for Cushing Disease IND 120,848 (10/10/2017)R01FD006106 · FDA · CEDARS-SINAI MEDICAL CENTER · fiscal years 2018 to 2024 · $493,827 awarded in 2024Same name and institution; not confirmed by an ID
- Training Program in Endocrinology, Diabetes, and MetabolismT32DK007770 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1999 to 2022 · $234,564 awarded in 2022Same name and institution; not confirmed by an ID
- Regulation of age-associated DNA damageR56AG070211 · NIA · CEDARS-SINAI MEDICAL CENTER · fiscal years 2021 · $342,350 awarded in 2021Same name and institution; not confirmed by an ID
- Treatment of pituitary Cushing disease with a selective CDK inhibitor, R-roscovitR21DK103198 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 2014 to 2015 · $210,897 awarded in 2015Grant number is on one of their registry trials
- Mechanisms of Pituitary TumorigenesisR01CA075979 · NCI · CEDARS-SINAI MEDICAL CENTER · fiscal years 1999 to 2012 · $277,093 awarded in 2012Same name and institution; not confirmed by an ID
- Cedars-Sinai Biobank and Translational Research Core Facility (CS-BRCF)G20RR030860 · NCRR · CEDARS-SINAI MEDICAL CENTER · fiscal years 2010 · $9,552,872 awarded in 2010Same name and institution; not confirmed by an ID
- Metabolic consequences of securin disruptionR01DK064169 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 2003 to 2007 · $306,828 awarded in 2007Same name and institution; not confirmed by an ID
- Quality Improvement Coalition for Human Subject ResearchS07RR018206 · NCRR · CEDARS-SINAI MEDICAL CENTER · fiscal years 2002 to 2003 · $100,000 awarded in 2003Same name and institution; not confirmed by an ID
- PITUITARY LIF EXPRESSION AND ACTIONR01DK050238 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1996 to 2000 · $273,537 awarded in 2000Same name and institution; not confirmed by an ID
- CEDARS - SINAI K-12 SCIENCE EDUCATION PROGRAMR25RR012220 · NCRR · CEDARS-SINAI MEDICAL CENTER · fiscal years 1998 to 1999 · $37,045 awarded in 1999Same name and institution; not confirmed by an ID
- TRAINING PROGRAM IN ENDOCRINOLOGY & DIABETEST32DK007682 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1992 to 1996 · $147,097 awarded in 1996Same name and institution; not confirmed by an ID
- ENDOCRINE ASPECTS OF HUMAN NEOPLASIAP01DK042792 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1991 to 1995 · $746,575 awarded in 1995Same name and institution; not confirmed by an ID
- INSULIN ACTION ON POLYPEPTIDE HORMONE EXPRESSIONR01DK034824 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1986 to 1992 · $151,426 awarded in 1992Same name and institution; not confirmed by an ID
- PITUITARY TUMOR CELL CULTURESR01DK041906 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1990 to 1991 · $100,453 awarded in 1991Same name and institution; not confirmed by an ID
- SMALL INSTRUMENTATION GRANTS15DK043429 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1990 · $21,220 awarded in 1990Same name and institution; not confirmed by an ID
- PREPARATIVE ULTRACENTRIFUGES15DK039406 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1987 · $17,323 awarded in 1987Same name and institution; not confirmed by an ID
- PITUITARY TUMOR CELL CULTURESR01DK033802 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1986 · $99,513 awarded in 1986Same name and institution; not confirmed by an ID
- INSULIN ACTION ON POLYPEPTIDE HORMONE EXPRESSIONR01AM034824 · NIADDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1985 · $103,293 awarded in 1985Same name and institution; not confirmed by an ID
- PITUITARY TUMOR CELL CULTURESR01AM033802 · NIADDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1985 · $108,502 awarded in 1985Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:29 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.Lancet · 2001473 citationsRCR 13.0
- Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.J Clin Endocrinol Metab · 2009223 citationsRCR 7.1
- Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.J Clin Endocrinol Metab · 1995214 citationsRCR 7.4
- Octreotide as primary therapy for acromegaly.J Clin Endocrinol Metab · 1998208 citationsRCR 6.7
- Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.J Clin Endocrinol Metab · 2010158 citationsRCR 5.2
- Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.J Clin Endocrinol Metab · 2015143 citationsRCR 6.4
- Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression.J Clin Endocrinol Metab · 2012132 citationsRCR 4.9
- 102 citationsRCR 3.6
- Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors.J Clin Endocrinol Metab · 199897 citationsRCR 2.2
- Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.J Clin Endocrinol Metab · 202082 citationsRCR 5.6